Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Teva Pharma Industries Ltd ADR (TEVAN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
226.78 0.00    0.00%
- Delayed Data. Currency in MXN ( Disclaimer )
Type:  Equity
Market:  Mexico
ISIN:  US8816242098 
S/N:  881624209
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 226.78 - 226.78
Teva ADR 226.78 0.00 0.00%

TEVAN Balance Sheet

 
Featured here, the Balance Sheet for Teva Pharma Industries Ltd ADR, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2023
31/12
 2023
30/09
 2023
30/06
 2023
31/03
Total Current Assets 12485 11425 12088 11501
Cash and Short Term Investments 3226 2249 2669 2143
Cash - - - -
Cash & Equivalents 3226 2249 2669 2143
Short Term Investments - - - -
Total Receivables, Net 3408 3385 3539 3435
Accounts Receivables - Trade, Net 3408 3385 3539 3435
Total Inventory 4021 4051 4109 4118
Prepaid Expenses 1255 1168 1228 1253
Other Current Assets, Total 575 572 543 552
Total Assets 43479 42088 43095 43456
Property/Plant/Equipment, Total - Net 6147 6028 6130 6171
Property/Plant/Equipment, Total - Gross 11784 - - -
Accumulated Depreciation, Total -5637 - - -
Goodwill, Net 17177 16885 17118 17799
Intangibles, Net 5387 5525 5738 5964
Long Term Investments 8 - - -
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 463 477 443 449
Other Assets, Total 3000 2986 2691 2807
Total Current Liabilities 12247 11394 11843 10411
Accounts Payable 2602 2280 2508 2381
Payable/Accrued - - - -
Accrued Expenses 5525 5274 5014 4633
Notes Payable/Short Term Debt - 500 - -
Current Port. of LT Debt/Capital Leases 1769 979 1980 1023
Other Current liabilities, Total 2351 2361 2341 2374
Total Liabilities 35353 34577 35387 34845
Total Long Term Debt 18184 18495 18698 19668
Long Term Debt 18161 18495 18698 19668
Capital Lease Obligations 23 - - -
Deferred Income Tax 606 544 534 550
Minority Interest 620 582 656 751
Other Liabilities, Total 3696 3062 3656 3465
Total Equity 8126 7511 7708 8611
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 57 57 57 57
Additional Paid-In Capital 27807 27780 27748 27719
Retained Earnings (Accumulated Deficit) -13534 -13870 -13950 -13086
Treasury Stock - Common -4128 -4128 -4128 -4128
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -2076 -2328 -2019 -1951
Total Liabilities & Shareholders' Equity 43479 42088 43095 43456
Total Common Shares Outstanding 1121.09 1120.97 1120.65 1120.41
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

TEVA Comments

Write your thoughts about Teva Pharma Industries Ltd DRC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Mar 23, 2024 9:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1% on a Friday with 9.13M volume someone is buying.
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Mar 13, 2024 10:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
Reply
0 0
Report
ritchie lee
ritchie lee Jan 22, 2024 1:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
long trend starting
Reply
5 0
Report
Ramba Łej
Kubizm Jan 22, 2024 1:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hopefully ! Ive been w8ing for it for 3 y xD
Reply
2 0
Report
Ramba Łej
Kubizm Sep 14, 2023 10:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
11,40 will hold as celling or convert to floor :)?
Reply
0 0
Report
Ramba Łej
Kubizm Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
Reply
2 0
Report
BumHunters Archer
JohnJenga Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
25 next year seems quite doable
Reply
0 0
Report
Michael Christensen
Michael Christensen Aug 02, 2023 6:00AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Somebody know the consensus for Q2 today ?
Reply
1 0
Report
Harel Cohen
Harel Cohen Aug 01, 2023 10:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
first real report of new CEO... it will be interesting
Reply
2 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email